The changing landscape of melanoma treatment

Bookmark and Share
Published: 22 Nov 2018
Views: 1803
Rating:
Save
Dr Eva Muñoz-Couselo - University Hospital Vall d'Hebron

Dr Eva Muñoz-Couselo speaks with ecancer at the EADO 2018 congress in Barcelona about the changing landscape of melanoma treatment.

Dr Muñoz-Couselo discusses target agents such as the BRAF inhibitor and that the agent must be combined with a MEK inhibitor.

She believes that combination treatments are the future but that superior biomarkers are needed to better determine which treatment is best for patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

The truth is that melanoma has changed quite a lot in the past 5-10 years and we have had several treatments which have changed the paradigm of this disease. We had a survival of less than one year and nowadays we are talking about more than 50% who are alive after three or four years receiving different treatments and, of course, regarding immunotherapy which is one of the treatments which has changed its paradigm.

Are targeted agents also being used?

The ones that are approved and the ones that we are using are the BRAF inhibitors which must be combined with a MEK inhibitor because we have several clinical trials that have demonstrated that combination is better than just a BRAF inhibitor because it has more efficacy and less toxicity. This is one of the standards for the BRAF mutated patients but also we have the option to give them immunotherapy, whether immunotherapy as an anti-PD-1 treatment or with the combination of ipilimumab plus nivolumab. But also we have several combinations which are now being developed just to open the landscape of options in this field.

What is the future for melanoma care?

The rise, of course, I think that there will be combinations, as we have talked together today in the symposium, because also monotherapies are giving us pretty good results. Of course we are not achieving 100% of survival that we, of course, would like to have for our patients. The problem with combinations is that there are several ones that are being developed but we don’t have pretty good biomarkers just to have the ability to identify which treatment is better for which patients and in the right time just to give it to them. There is so much work being done in research for looking for biomarkers.

Can you explain the effect of staging for neoadjuvant and adjuvant therapies?

One of the things that has changed quite a lot in the past one or two years is that we have introduced treatments which have been very positive in the metastatic setting, we have translated into the adjuvant setting and nowadays in the neoadjuvant. We are seeing that these treatments are pretty active also in the adjuvant and neoadjuvant setting and the future is to develop treatments in the early stages just to avoid patients to be metastatic. Of course also combinations are being tested in these settings as well.

What is your take home message from the presentations?

The most hot topic now in melanoma is that we have very pretty good treatments but we have to improve. The future will be for combinations but there’s a huge need for biomarkers and a lot of effort must be done just to identify the hot test that we will have just to give the better treatment for each patient at the right time.

Related Videos

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of...
Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands
Neoadjuvant ipilimumab and nivolumab  immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 D...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-defic...
Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )
5 Jun 2022
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refrac...
Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid,...
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )
21 Apr 2022
Significance of gut microbiota in patients receiving CAR T cell immunotherapy
Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA
Significance of gut microbiota in patients receiving CAR T cell immunotherapy ( Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA )
17 Dec 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )
8 Jun 2021
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 inserti...
Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passa...
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )
29 Mar 2021